menu
    • menu
    [{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Translational Research In Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Translational Research In Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Giredestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Research In Oncology \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ Roche"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Giredestrant","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Translational Research In Oncology \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Translational Research In Oncology \/ Roche"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","graph1":"Oncology","graph2":"Approved","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Translational Research In Oncology \/ Translational Research in Oncology","highestDevelopmentStatusID":"12","companyTruncated":"Translational Research In Oncology \/ Translational Research in Oncology"},{"orgOrder":0,"company":"Translational Research In Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ribociclib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Translational Research In Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Translational Research In Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Translational Research In Oncology \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Translational Research In Oncology

    Menu

    Translational Research In Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Translational Research In Oncology

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Translational Research In Oncology

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribociclib,Anastrozole

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novartis Kisqali® Phase III NATALEE Trial Meets Primary Endpoint at Interim Analysis Demonstrating Clinically...

                            Details : Kisqali® (ribociclib) is the only USFDA approved category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with an AI.

                            Brand Name : Kisqali

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 27, 2023

                            Lead Product(s) : Ribociclib,Anastrozole

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Translational Research In Oncology

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Translational Research In Oncology

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novartis Kisqali® Adds One More Year of Survival Benefit for Broadest Set of Patients, Including Those With A...

                            Details : Kisqali (ribociclib) is a unique CDK4/6 inhibitor, consistently demonstrating statistically significant OS benefit while maintaining or improving quality of life across three Phase III trials, regardless of patient or disease characteristics.

                            Brand Name : Kisqali

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 09, 2022

                            Lead Product(s) : Ribociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Translational Research In Oncology

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Translational Research In Oncology

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Giredestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TRIO Enrols First Patient in Global Phase 3 Giredestrant Early Breast Cancer Trial

                            Details : Giredestrant is an oral selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging anti-tumour activity both alone and in combination with palbociclib in estrogen-receptor positive (ER+) metastatic breast cancer pati...

                            Brand Name : GDC-9545

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 31, 2021

                            Lead Product(s) : Giredestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Translational Research In Oncology

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Translational Research In Oncology

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Giredestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule

                            Details : Giredestrant is an oral selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging tumour activity both alone and in combination with palbociclib in estrogen-receptor positive (ER+) metastatic breast cancer patients.

                            Brand Name : GDC-9545

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 06, 2021

                            Lead Product(s) : Giredestrant,Palbociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Translational Research In Oncology

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Translational Research In Oncology

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial

                            Details : Ribociclib belongs to a class of targeted therapies called CDK4/6 inhibitors. Cyclin-dependent kinases 4 and 6 are proteins that help regulate cell replication and proper cell cycle function.

                            Brand Name : Kisqali

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 21, 2021

                            Lead Product(s) : Ribociclib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth